Researchers evaluated camupepimut, an off-the-shelf vaccine designed to target common KRAS mutations, in a randomized phase 2 trial reported in Nature Medicine. The study enrolled 144 patients with resected pancreatic ductal adenocarcinoma (stages 1–3) who had completed surgery and chemotherapy and showed no radiologic recurrence at enrollment. Investigators randomized participants in a 2:1 ratio: 96 received the vaccine and 48 entered observation. The primary outcome was disease-free survival; secondary analyses included T-cell immune responses and safety assessments.
Camupepimut delivers mutation-targeted components to lymph nodes with the goal of training T cells to recognize tumor cells harboring mutant KRAS. The vaccine is intended as a broadly applicable product against multiple common KRAS variants rather than a personalized, tumor-specific construct. The article did not provide granular details on dose, injection schedule, or the number and timing of boosters used in the phase 2 protocol.
Immune readouts strongly favored the vaccinated cohort. Investigators observed activation of KRAS-targeting T cells in nearly 99% of vaccine recipients. In a subset evaluated for magnitude of response, T-cell activity increased by more than ninefold in 82.2% of participants assessed. Those are sizable immunologic signals, measured and reported by the study team.
Despite these immune results, the trial did not meet its primary endpoint for disease-free survival. Median disease-free survival was 23.8 months in the vaccine arm and 21.2 months in the observation arm. The difference did not achieve statistical significance according to the study report. At the 6-month landmark, 75.7% of vaccinated patients were disease-free versus 61.7% in the control group—a numerical early separation that suggested a possible short-term benefit but that again did not translate into a statistically significant improvement over the full follow-up period.
The investigators carried out further exploratory analyses to identify patient subsets who might derive greater benefit. Patients without detectable circulating tumor DNA (ctDNA) at baseline appeared to have better disease-free survival after vaccination than those with detectable ctDNA. The team also noted an association between stronger T-cell responses and longer disease-free intervals. The original report did not provide p-values, hazard ratios, or confidence intervals for these subgroup observations in the summary available here.
Safety data were straightforward in the published summary: the vaccine was generally well tolerated. The authors reported no treatment-related deaths and no adverse events that led participants to discontinue the trial intervention. The article did not list specific adverse-event types or rates beyond those high-level safety statements.
Independent clinicians told Medical News Today that the immune activation documented in the trial is meaningful given pancreatic cancer’s historical resistance to immunotherapy. One surgical oncologist said the findings show pancreatic tumors can mount responses when patients develop strong vaccine-induced immunity. Another immunotherapy specialist emphasized that antigen recognition is only the first hurdle; the tumor microenvironment must also permit immune clearance, and combination approaches may be required.
Both external commentators noted the trial’s limited size and the finite vaccination period as potential reasons a survival benefit was not detected. They argued that extended vaccination schedules, additional booster dosing, or rational combinations with agents that reverse tumor-mediated immunosuppression could change clinical outcomes in a larger randomized setting.
Readers should interpret the phase 2 results within clear constraints. The study enrolled 144 participants and was powered and conducted as a phase 2 randomized trial; the report did not specify detailed statistical thresholds or full analytic tables in the summary provided. The vaccination regimen details and precise adverse-event frequencies were not included in the source text. Those methodological specifics will matter for interpreting efficacy and safety in broader practice.
The study team plans to advance camupepimut into phase 3 testing. Planned elements mentioned by the authors include evaluating different booster strategies and testing the vaccine in combination with other treatments, though the source did not list exact combination partners or schedules. Open questions remain: whether longer or more intense vaccination will convert the early immune signals into a durable clinical benefit, which patient subgroups will gain the most (for example, ctDNA-negative patients), and how best to pair the vaccine with immunomodulatory agents to overcome tumor-driven immune suppression.
The article ends with those unresolved trial questions and the prospect of a phase 3 program; it does not offer regulatory timelines or definitive clinical recommendations. The full Nature Medicine report contains the detailed data and statistical analyses necessary for clinicians and investigators to evaluate the vaccine’s clinical potential further.